Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

NCT01215110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Tuberculosis

Interventions

DRUG: TMC207
DRUG: Rifafour e-275 mg

Sponsor

Global Alliance for TB Drug Development